GlassScriptPhysician profile
Addi Georgantzis
NPI 1083280317
$2,072.73
in general payments reported to CMS, 2019-2025
12 companies · $1,594 in 2025
The $1,594 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $224 · 2023: $79.46 · 2024: $175 · 2025: $1,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $980 · Food and Beverage: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $980.00 |
| Food and Beverage | $868.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $1,003.05 | 2025 | Epkinly |
| Janssen Biotech, INC. | $378.48 | 2023-2025 | Rybrevant, Carvykti, Tecvayli |
| Sanofi-Aventis U.S. LLC | $156.51 | 2022-2024 | |
| Amgen INC. | $99.00 | 2022 | |
| Immunocore Limited | $81.82 | 2024-2025 | Kimmtrak |
| Celgene Corporation | $73.38 | 2024-2025 | Breyanzi |
| Abbvie INC. | $67.63 | 2024-2025 | |
| Genentech USA, INC. | $58.04 | 2025 | Itovebi, Columvi, Lunsumio |
| Taiho Oncology, INC. | $53.69 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $44.46 | 2023 | Imfinzi, Lynparza |
| Astellas Pharma US INC | $41.17 | 2024-2025 | Xospata |
| Daiichi Sankyo INC. | $15.50 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Addi Georgantzis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.